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The kynurenine pathway of tryptophan metabolism accounts for most of the 
tryptophan that is not committed to protein synthesis and includes compounds 
active in the nervous and immune systems. Kynurenine acts on the aryl 
hydrocarbon receptor, affecting metabolism of xenobiotics and promoting 
carcinogenesis. Quinolinic acid is an agonist at N-methyl-D-aspartate receptors 
(NMDAR), but is also pro-oxidant, has immunomodulatory actions and 
promotes the formation of hyperphosphorylated tau proteins. Kynurenic acid 
blocks NMDARs and 7-homomeric nicotinic cholinoceptors but is also an 
agonist at the orphan G-protein-coupled receptor GPR35. 3-hydroxykynurenine 
and 3-hydroxyanthranilic acid have pronounced redox activity and regulate T 
cell function. Cinnabarinic acid can activate metabotropic glutamate receptors. 
The aim of this review is to highlight the increasing range of molecular targets 
for components of the kynurenine pathway, in both the nervous and immune 




The kynurenine pathway 
     Apart from the tryptophan used in protein synthesis, most of this amino acid 
in mammals is oxidised along the kynurenine pathway. Only around 1% of 
tryptophan is used for the synthesis of 5-hydroxytrpytamine (5-HT). For many 
years, most compounds along the pathway (Figure 1) were thought to have little 
biological activity until quinolinic acid was shown to be an agonist at glutamate 
receptors sensitive to NMDA [1] and kynurenic acid was found to be an 
antagonist at these and other ionotropic glutamate receptors [2]. These two 
compounds have been the focus of attention on the kynurenine pathway for 
over 30 years [3,4]. In parallel with work on the central nervous system (CNS), 
however, there has been growing interest in the role of kynurenines in the 
immune system, and the last few years have seen the identification of more 
molecular targets acted on by quinolinic acid, kynurenic acid or other 
components of the pathway. The key enzymes, indoleamine-2,3-dioxygenase 
(IDO) and kynurenine-3-monoxygenase (KMO) are also potential drug targets. 
The aim of this review is to highlight the increasing range of molecular targets 
now recognised in the nervous and immune systems in relation to their 
relevance to disease and drug development. 
     
Kynurenine metabolites and their receptors in disease 
Quinolinic acid 
     In addition to its ability to activate NMDARs selectively, quinolinic acid can 
generate reactive oxygen species (ROS). This activity can produce substantial 
oxidation of cellular lipids, especially in the presence of transition metal ions [5]. 
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The axon-sparing neuronal loss produced by quinolinic acid in vivo may be due 
partly to formation of ROS [6] although it certainly also involves activation of 
NMDARs. 
     Acting on human primary astrocytes, excitotoxic concentrations of quinolinic 
acid can also promote the expression and secretion of some of the more potent 
chemokines and proinflammatory cytokines responsible for orchestrating the 
early phases of innate immune responses. In this context, quinolinic acid 
promotes the production of interleukin-1 (IL-1
chemoattractant protein-1 (MCP-1), as well as IL-8, Regulated on Activation, 
Normal T-cell Expressed and Secreted (RANTES) and several related 
chemokines and their receptors able to promote inflammatory responses [7,8] to 
a degree comparable with tumour necrosis factor- (TNF- - 
(IFN-  This may indicate an ability of quinolinic acid to initiate inflammation 
within the CNS or to enhance it when it is partly established as part of a disease 
process such as Alzheimer's disease (AD). 
     The amyloid plaques found in the brains of patients with AD are associated 
with high concentrations of quinolinic acid [9] but the compound is also co-
localised with hyperphosphorylated tau proteins which form the paired helical 
filaments in this disorder [10]. Quinolinic acid inhibits the phosphatase-mediated 




     Two early studies of the anti-epileptic actions of kynurenic acid 
independently reported that its suppression of epileptiform bursts in 
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hippocampal slices could not be entirely explained by blockade of NMDARs 
[11,12] (Figure 2). However, a new receptor target was later identified as 
homomeric 7-nicotinic cholinoceptors (7NR), where kynurenic acid was a 
non-competitive antagonist [13]. The effect was observed initially in neuronal 
cultures, where kynurenic acid appeared more active as an antagonist of 
7NRs than NMDARs. However, this differential potency did not apply to 
neurones in more intact, multicellular preparations such as slices. A later 
examination of hippocampal interneurones confirmed that kynurenic acid could 
block 7NR on these cells excited by exogenously applied agonists or 
synaptically released acetylcholine, although with a potency that was not 
fundamentally different from that which blocked NMDAR [14]. Thus, the 
sensitivity of 7NR is probably dependent on experimental conditions and 
location, differing also between synaptic and extrasynaptic sites. Sensitivity may 
also change with age [15]. In addition, kynurenic acid produced endogenously 
within brain slices from kynurenine is better able to block NMDAR and 7NR 
than kynurenic acid which is added exogenously [15], so that its physiological 
activity at this site may be underestimated. 
     AD.  These data are especially relevant to the treatment of Alzheimer's 
disease. Agonists acting at 7NR are particularly good at facilitating learning 
and memory processes in animal models and in patients with AD [16,17]. 
Conversely, a loss of cholinergic projections from the septum to the 
hippocampus or from nucleus basalis to the neocortex results in substantial 
deficits in learning, as does the administration of cholinoceptor antagonists. 
Although there are relatively few studies of the kynurenine pathway in patients 
with AD, IDO is activated in the disease leading to a high kynurenine:tryptophan 
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ratio in blood [18, 19]. This would be expected to raise the endogenous levels of 
kynurenic acid which, by blocking glutamate and nicotinic receptors, could 
contribute to cognitive dysfunction. 
     However, the effects of compounds that inhibit KMO are not limited to 
increasing the levels of kynurenic acid. A recent study showed that KMO 
inhibition also produces a decrease in the levels of glutamate in a transgenic 
mouse model of Alzheimer's disease. This was associated with a reduction in 
the loss of synapses in the brain, with improved memory in a spatial learning 
task and reduced anxiety behaviour [20]. This would be consistent with the view 
that part of the neurodegeneration seen in Alzheimer's disease is caused by the 
excitotoxic effects of endogenous glutamate. Since KMO inhibition should also 
reduce the formation of quinolinic acid, it is possible that this NMDA agonist 
may also have contribute to the excitotoxicity in AD, but its role was not 
assessed directly in that study. 
     HD. There are many neurochemical similarities observed in the post mortem 
striatum of patients with HD and animal models produced by quinolinic acid 
injections [21,22], with additional aspects of motor function in common [23]. 
Patients also exhibit reduced levels of kynurenic acid in the brain [24], although 
3HAA concentrations are raised, consistent with the increased concentrations of 
quinolinic acid found in the brains of animal models of HD [25,26]. In the most 
commonly used R6/2 mouse model of the disorder, KMO activity is increased 
and inhibition of the enzyme prolongs the life span of the animals as well as 
protecting neurons and synapses and suppressing microglial activation [20]. 
Recent clinical studies have obtained strong support for a role of kynurenines 
with the finding of highly significant correlations between the blood 
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concentrations of kynurenine and the number of DNA codon repeats (CAG) in 
the abnormally extended nucleotide sequence of the huntingtin gene [27]. 
Together there results are consistent with the view that the molecular aberration 
in HD is associated with altered kynurenine metabolism, which could account 
for at least some of the symptoms and progression of the disease. 
     Schizophrenia. In schizophrenia, the suppression of dopaminergic function 
by neuroleptic drugs can reduce the early, positive symptoms which are caused 
by overactivity of the ventral tegmental projections to the striatum and nucleus 
accumbens. Classical drugs have little effect on later, negative symptoms which 
are associated with underactivity of dopaminergic projections to prefrontal 
cortex [28]. Underlying these disturbances is a hypo-glutamatergic state [29]  
the induction of which, in animals, is widely used to model schizophrenic 
symptoms [30]. Thus, compounds that block NMDARs, such as phencyclidine, 
can induce many of the cardinal symptoms of schizophrenia such as a loss of 
pre-pulse inhibition [31]. A hypoglutamatergic state could be produced by raised 
levels of kynurenic acid, and several studies show up to five times the normal 
level of kynurenate in the cerebrospinal fluid (CSF) of schizophrenic patients 
[32,33]. The administration of kynurenic acid (directly or via its precursor, 
kynurenine), produces a reduction of extracellular dopamine concentrations, as 
seen in the prefrontal cortex in schizophrenia. Conversely, reduced kynurenic 
acid concentrations promote dopamine release in striatum [34] and 
hippocampus [35], which may account for the wide spectrum of cognitive 
dysfunction in schizophrenia. The mechanism of this effect is unclear at the 
cellular and network level, although it has been suggested that the interaction 
results from a blockade by kynurenic acid of glutamate or 7NR on 
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dopaminergic nerve terminals or local astrocytes [36]. There is a diminished 
activation of 7NRs in schizophrenia, and the administration of agonists acting 
at 7NRs can reduce many of the positive and negative aspects of cognitive 
dysfunction in schizophrenia and animal models [37,38].  
     Slightly complicating this picture is a report that kynurenic acid may facilitate 
activity of AMPA receptors by modulating their desensitisation  [39] and that it 
produces antagonism of AMPA when used at higher concentrations. To date, 
however, these results have not been confirmed and may represent, at best, a 
minor action of kynurenic acid. 
     Collectively these data suggest that the blockade of glutamate, NMDARs 
and 7NRs by kynurenic acid could account for many of the learning and 
cognitive problems in AD and schizophrenia. Indeed, deletion of the enzyme 
which synthesises kynurenic acid – kynurenine aminotransferase II (KATII) – 
has a pro-cognitive effect in animals [40], supporting the view that even normal 
levels of kynurenate may have a limiting effect on cognitive function. In addition, 
the plasma concentration of kynurenic acid increases with age in humans and 
could contribute to age-related deficiencies in memory and cognition [41].  
 
Alternative molecular targets for kynurenic acid  
GPR35 
     Another target of kynurenic acid may be the erstwhile orphan G-protein-
coupled receptor GPR35, at which kynurenic acid is one of the most potent 
endogenous agonists yet identified [42] (Figure 2). The highest levels of GPR35 
are in the intestine where, in patients with inflammatory bowel disease, 
kynurenic acid levels are significantly greater than in control subjects [43]. The 
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receptor has been implicated in several aspects of gastrointestinal dysfunction 
including the development of gastric cancer [44]. Its role in the CNS is less clear 
although loss of GPR35 may underlie at least one form of mental retardation 
[45]. The agonist activity of kynurenic acid could therefore be important in the 
early development of the CNS. Indeed, recent data demonstrate that increasing 
kynurenic acid levels prenatally leads to marked changes in the expression of 
neurodevelopmental proteins in postnatal life [46]. 
     Expression of GPR35 in immune cells occurs in neutrophils, monocytes, T 
cells and dendritic cells, but less so in natural killer (NK) cells and eosinophils. 
Amongst peripheral blood cells, GPR35 expression is greatest in circulating 
monocytes which, in the presence of kynurenic acid, bind firmly to endothelium, 
suggesting a role for this ligand-receptor combination in monocyte extravasation 
[47]. In monocytes, macrophages and glial cells, GPR35 interaction with 
kynurenic acid down-regulates the proinflammatory phenotype induced by 
bacterial lipoloysaccharides (LPS), notably reducing TNF- and high-mobility 
group box 1 protein (HMGB1) [48] (Figure 2). A proposed intracellular 
mechanism for this effect is the lowering of intracellular calcium, mediated by 
GPR35-linked adenylate cyclase inhibition and reduced intracellular cAMP; a 
similar explanation has been advanced to explain reduced calcium-dependent 
release of glutamate from GPR35-expressing glia treated with kynurenic acid 
[42]. There is currently little information available about other immune system 
cells that express GPR35, except for invariant natural killer cells (iNKT) which, 
on specific stimulation by glycolipids (presented by antigen presenting cells) 
produce a large variety of cytokines and chemokines [49]; GPR35 engagement 
 10 
by kynurenic acid downregulates IL-4 but not IFN- and probably has other 
actions yet to be identified. 
      
Growth factors 
      Although the blockade of glutamate receptors by kynurenic acid may cause 
the cognitive dysfunction discussed above, the same blocking action can 
protect the brain against the excitotoxic effects of abnormally high glutamate 
receptor activation. This protective activity may be enhanced by effects on 
growth factors since kynurenic acid can increase the expression of nerve 
growth factor (NGF) in glial cells [50,51]. NGF is of special importance because 
of its regulation of proliferation and subsequent maintenance of cholinergic 
neurones in the CNS, and hence of relevance to AD and schizophrenia [52]. In 
contrast, kynurenic acid reduced the release of fibroblast growth factor-1 (FGF-
1) in several different experimental models [53], so that its net effects on cell 
viability may depend on a balance of changes in different growth factors. 
Although these results are exceptionally interesting for understanding the 
neuroprotective effects of kynurenic acid, therefore, work should be extended to 
other growth factors. For example, because kynurenic acid can enhance 
proliferation of some glial cells, it would be of value to examine the expression 
and release of gliotropic factors as well as brain-derived growth factor (BDNF). 
 
A kynurenine receptor?  
     A most surprising discovery has been that kynurenine itself – a compound 
regarded as being almost devoid of biological activity – can act at the aryl 
hydrocarbon receptor (AHR) [54] (Figure 3). The AHR is a cytosolic 
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transcription factor which is the primary binding site for the potent cellular toxin 
2,3,7,7-tetrachlorodibenzo-p-dioxin, (often known as ‘dioxin’). The receptor is a 
component of the ‘xenobiotic response element’ which is important in the 
detection of foreign substances. The AHR acts on a range of major 
metabolising enzymes including phase I and phase II enzymes such as 
CYP1A1, CYP1A2 and CYP1B1 and gives animals the ability to detect and 
respond to a wider range of xenobiotics and toxins than would otherwise be 
possible. The AHR appeared early in evolution and exists in a variety of species. 
Kynurenine may be the primary natural, endogenous ligand at the AHR, 
promoting protection of the organism, reducing illness triggered or caused by 
chemicals, and even prolonging survival [54,55]. This view is supported by work 
in which the AHR has been deleted, leaving animals with physiological 
aberrations and slowed development [56,57]. 
    The AHR may be associated with fundamental aspects of cell biology 
including the proliferation and differentiation of cells early in embryonic 
development, especially in the blood and lymphoid tissues as well as neurons. 
This would explain a requirement for the AHR in tissue formation [58].  In 
vertebrates, the role of AHR in development extends to the maturation of cells 
in the immune and nervous systems. Expression of AHR has been 
demonstrated in both innate and adaptive immune cells and, with few known 
exceptions, ligand engagement determines anti-inflammatory and tolerogenic 
cell phenotypes. Gene knock-out studies indicate that macrophages with intact 
AHR produce fewer proinflammatory mediators on stimulation with LPS or silica 
than those lacking AHR [59,60].  
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     Dendritic cells (DCs) present antigens to naive T cells and are a crucial link 
between innate and adaptive immunity; whether DCs exhibit a predominantly 
immunostimulant or immunosuppressive phenotype determines T cell 
responses. Immunostimulants such as LPS promote the expression of the AHR 
in DCs, and this expression is in turn required for the induction of IDO [61]. 
Furthermore, co-cultures of AHR(-/-)DCs and naïve T cells suppressed 
differentiation of the latter into Treg cells, while addition of kynurenine to this 
system restored differentiation into anti-inflammatory Treg cells and reduced 
differentiation into the highly inflammatory Th17 cells [55]. Thus, kynurenine 
acts on DCs to produce a powerfully anti-inflammatory action (Figures 3, 4). 
Whether this effect of kynurenine is also mediated through the AHR remains 
unclear.  
   In the adaptive immune system, AHRs are also constitutively expressed on 
naïve CD4+ T cells, and on AHR-kynurenine engagement differentiate into 
tolerizing Foxp3+ Treg cells, (which exert a constant restraining influence over 
both Th1 and Th2 helper cell populations) rather than to the pro-inflammatory 
Th17 cells [62,63]. One result of this is to promote self-tolerance, reducing the 
development of autoimmune disorders. The effect is potentiated by the 
activation (by kynurenine) of AHRs on DCs, an action which inhibits DC 
maturation and - because these are major antigen presenting cells - further 
inhibits immune surveillance. This also reduces tumour recognition, and thus, 
together with its propensity for increasing cell proliferation, AHR activation by 
kynurenine promotes tumour survival, growth, migration and metastasis [64]. 
     Since kynurenine is generated when IDO or TDO are activated in pro-
inflammatory microenvironments by mediators such as IFN- or TNF-, the 
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discovery of AHR as a kynurenine or kynurenic acid receptor may help to 
provide the sought-after link between chronic tissue inflammation and the 
induction of cancer. The future prospects for integrating the biology of 
kynurenines in the nervous and immune systems with carcinogenesis, with the 
kynurenine pathway emerging as an important new target for drug development, 
is immensely exciting. 
     Finally, it should be noted that, in addition to kynurenine, kynurenic acid may 
also be an agonist at the AHR with nanomolar potency [65], able to induce 
expression of the multi-functional and tumour-associated cytokine IL-6 (Figures 
3, 4). 
 
The 3-hydroxy compounds 
     Both 3-hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid (3HAA) 
(Figure 1) show significant cellular toxicity. The neurotoxicity of 3-HK is 
mediated primarily through its production of ROS, which initiate apoptosis [66]. 
The toxicity is probably produced at an intracellular site because the compound 
must be taken up by the large neutral amino acid transporter to exhibit toxicity. 
As with other redox active compounds, 3-HK and 3HAA acid they show pro-
oxidant or anti-oxidant activity, depending on the local oxidative environment, 
and thus regulate the oxidative status of tissues. Given the acknowledged 
importance of ROS in tissue function and pathology, fluctuations in 
concentration of 3-HK or 3-HAA could play a significant role in the initiation, 
progress or remission of diseases involving oxidative stress, which includes 
many neurodegenerative CNS disorders.  
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     3-HAA also inhibits nitric oxide synthase in macrophages [67] and can 
readily be nitrosylated to oxadiazole compounds, a property shared with 3-HK 
[68]. These behaviours could seriously compromise the biological functions of 
NO and merit further investigation. 
     Certainly, the levels of 3-HAA can change dramatically. In a study of patients 
newly diagnosed with osteoporosis, plasma levels of 3-HAA were less than 10% 
of those in control subjects. Over two years’ treatment with standard drugs, this 
level rose to control values in parallel with significant improvements in bone 
density [69]. Intriguingly, this leap in plasma 3-HAA concentrations was 
accompanied by the converse change in anthranilic acid, another kynurenine 
metabolite whose origin, metabolism and biology remain largely unexplored. A 
similar reversal in the ratio of 3-HAA and anthranilic acid has been discovered 
in patients with Huntington's disease (HD), stroke and chronic brain injury [70]. 
     Cinnabarinic acid is a metabolite of 3-HAA formed by its oxidative 
dimerisation. This compound is able to induce apoptosis of T cells with a 
potency about ten times that of 3-HAA itself [71], and it may, therefore, be the 
compound responsible for some of the effects hitherto attributed to 3-HAA. In 
addition, cinnabarinic acid activates mgluR4 [72], raising the possibility that it 
may have relevance to the development or treatment of several CNS disorders, 
especially Parkinson's disease [73].  
 
A wider role in the immune system 
     In addition to the effects that kynurenines have on immune function via the 
AHRs, there is increasing evidence for more generalised actions on the immune 
system. The inhibitory effect of IFN- on the growth and proliferation of 
 15 
Toxoplasma parasites cultured with fibroblasts results from its activation of the 
first enzyme in the kynurenine pathway – IDO [74]. The activation produced a 
suppression of cell proliferation which was restored by adding tryptophan, giving 
rise to the ‘tryptophan depletion’ hypothesis which posits that the activity of IDO 
reduces the local concentrations of tryptophan, which in turn limits protein 
synthesis to rapidly dividing cells.  
     That observation marks the start of interest in kynurenine effects in the 
immune system. A second landmark discovery was that inhibition of IDO, using 
1-methyl-tryptophan, produced a loss of embryos in pregnant rats [75]. The 
proposed explanation was that the placenta normally upregulated IDO to 
maintain low tissue concentrations of tryptophan, thus inhibiting the activity and 
proliferation of maternal T cells that would normally detect and destroy the 
allogeneic foetus. By inhibiting IDO, therefore, this tryptophan depletion could 
not be induced and T cell attack proceeded successfully to destroy the foetus. 
This pioneering work diversified rapidly into investigating the links between 
raised levels of IDO and immunotolerance in both transplantion and cancer [76] 
(Figure 4).  
     Much of the immune tolerance to tumours is particularly attributed to the 
proliferation of regulatory T cells (Treg cells) expressing the Foxp3+ transcription 
factor [77]. These cells depress the activity of aggressive T cell populations 
including CD8+ cytotoxic (anti-tumour) cells, DCs and NK cells. IDO activation 
in a sub-population of DCs initiates a positive feedback cycle leading to an 
expansion in the numbers of Foxp3+Treg cells by promoting their differentiation 
from naïve CD4+ T cells, a change which is greatly enhanced in the presence 
of transforming growth factor- (TGF-) and IL-6. These Treg cells then act back 
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on DCs to induce further IDO [78] (Figure 4). Also, 3-HAA stimulates the 
production of TGF-, which further potentiates Treg cell formation. Overall, the 
increased numbers of Foxp3+Treg cells, involving the expression of IDO activity, 
suppresses immune function and generates a pronounced anti-inflammatory 
effect. This is further enhanced by a direct inhibition of Th1 cells by 3-HAA [79] 
(Figure 4).  
     In addition to stimulating TGF- production, 3-HAA acts directly upon Th1 
cells to suppress their pro-inflammatory activity, but has no discernible action on 
Th2 cells [78-80] although IDO activation overall may promote Th2 function [81]. 
These two T cell populations normally exist in a delicate balance, with Th1 cells 
generating IFN helping to sustain macrophage activation and release the 
powerfully pro-inflammatory TNF- as well as other deleterious substances 
including ROS. The combination of these Th1-induced factors is anti-microbial 
but also tends to attack allogeneic cells, producing rejection of tissue allografts 
and foetal resorption or abortion. Th2 cells generate IL-4 which acts as a brake 
on the activation of macrophages by IFN, thus imposing an anti-inflammatory 
restraint on the system and contributing to graft retention and foetal protection 
[82, 83]. The preferential inhibition of Th1 cells, therefore, confers on 3-HAA an 
overall immunoprotective influence [82]. 
     In fact, IDO activation may not be the only trigger for this cascade. IFN- and 
other pro-inflammatory cytokines also induce kynurenine-2,3-dioxygenase 
(KMO) and kynureninase so that, as long as kynurenine is available, the levels 
of 3-HK, 3HAA and quinolinic acid generated by DCs will be sufficient to 
regulate the activity of immune system cells [84]. The resulting state of immune 
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tolerance (tolerogenesis) seems to be produced by the kynurenine metabolites 
rather than by tryptophan depletion. 
     Although IDO is widely distributed in many tissues, the closely related 
enzyme tryptophan-2,3-dioxygenase (TDO) is largely confined to the liver. It 
also converts tryptophan to kynurenine and its subsequent metabolites and will 
therefore reduce T cell activity and immune surveillance, thus increasing the 
possibility of tumour formation as discussed above for IDO. In contrast to IDO, 
the activity of TDO is induced by glucocorticoids [85,86]. and, because the 
secretion of these steroids occurs in response to stress, this link may contribute 
to the greater incidence of cancer resulting from chronic stress, for which TDO 
inhibitors might present a potential treatment [87,88]. 
     Kynurenine metabolites help to regulate secretion of the tolerogenic Human 
Lymphocyte Antigen-G (HLA-G) [89]. In patients with HD, blood levels of this 
antigen correlate significantly with the levels of kynurenine metabolites in the 
blood. There is also a strong correlation between tryptophan metabolism and 
the size of the abnormally extended huntingtin protein which is believed to 
cause the disorder [27], supporting the increasing evidence for a significant 
pathological role for kynurenines in Huntington's disease [22]. 
 
Kynurenines and drug development 
     The discovery that kynurenine-derived metabolites of tryptophan could 
modulate the level of glutamate receptor activation focussed early interest on 
their potential roles in neurodegenerative disorders in which over- or under-
activity of those receptors could produce excitotoxicity and neurodegeneration, 
or a general suppression of excitatory neurotransmission respectively. As this 
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review indicates, some of those original thoughts may still be highly relevant in 
disorders such as AD and HD, where compounds that inhibit KMO in particular 
could slow the rate of neuronal loss. In schizophrenia, the contrary situation is 
encountered, with raised kynurenic acid levels that could be normalised by 
development of selective inhibitors of KAT II [21]. The pro-cognitive actions of 
KAT inhibition have been adequately confirmed by the finding that deletion of 
KAT II results in a similar degree of cognitive enhancement and memory 
function [40]. The potential value of the kynurenine pathway for the 
development of new drugs acting in disorders such as these, in which a degree 
of neuronal damage is involved, has been discussed previously [90] 
     In addition, the identification of a range of molecular targets such as GPR35, 
with potential roles in inflammatory disorders, raises the possibility of 
developing new generations of anti-inflammatory compounds based on the 
chemical structure of kynurenic acid. Similarly, as knowledge develops of the 
actions performed by the AHR, the recognition of kynurenic acid as the possible 
natural ligand raises an entirely new means of viewing the possible 
pharmacological regulation of xenobiotic metabolism. 
     Finally, the parallel work that has developed since the early 1980s of the 
actions of kynurenines in the CNS and their effects in the immune system seem 
to be moving closer towards an integrated view of their interaction. That may in 
turn result in the development of compounds that can regulate changes in the 
processes of CNS neurotransmission directly, but which can also modify the 
development and progression of inflammatory reactions that increasingly seem 
to underlie chronic CNS disorders such as AD and HD, but may also be 
relevant to conditions such as multiple sclerosis (MS) [91] and infection-induced 
 19 
dementias [92]. This is certainly a pathway that is likely to become more 
intriguing in the future. 
 
Concluding remarks 
     Although the links between tryptophan metabolism to kynurenines and to 5-
HT should not be forgotten, future research might benefit greatly from an 
increasing attention on the oxidative metabolism of tryptophan along the 
kynurenine pathway. The potential sites for interference may be under- or over-
activated by their ligands, mutated genetically or modified epigenetically and 
should be regarded as druggable targets for pharmacological development with 
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A summary of the main compounds which constitute the kynurenine pathway for 
the oxidative metabolism of tryptophan. The pathway is usually referred to in 
this way after the initial stable product of tryptophan oxidation, kynurenine, 
which was originally isolated from canine urine in the nineteenth century and 




The major cellular and molecular targets of kynurenic acid. The blockade of 
NMDA receptors was the first specific site of action to be identified [2], followed 
nearly 20 years later by blockade of 7 nicotinic receptors [13]. Increasing 
interest is being shown in a range of sites in the immune system with potential 




Potential sites at which kynurenine, for long regarded as biologically inactive, 







The first enzyme in the kynurenine pathway, indolamine-2,3-dioxygenase (IDO) 
plays a key role in regulation of the immune system by virtue of its activation by 
mediators such as interferon-. In addition to the effects of kynurenic acid and 
kynurenine itself, some features of the kynurenine pathway on the balance of 
inflammatory status are mediated by 3-hydroxykynurenine and 3-


































A summary of the main compounds which constitute the kynurenine pathway for 
the oxidative metabolism of tryptophan. The pathway is usually referred to in 
this way after the initial stable product of tryptophan oxidation, kynurenine, 
which was originally isolated from canine urine in the nineteenth century and 


































7NR: 7-nicotinic cholinoceptors 
AHR:  aryl hydrocarbon receptor 
AMPA: -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
CD8+ : cytotoxic (anti-tumour) T cells  
CSF :  cerebrospinal fluid 
DC:  Dendritic cells    
GPR35: G-protein-coupled receptor 35.  
3-HAA 3-hydroxyanthranilic acid   
3HK:  3-hydroxykynurenine:  
HLA-G: Human Lymphocyte Antigen-G 
HMGB1 :high-mobility group box 1 protein 
IDO:   indoleamine-2,3-dioxygenase  
IL-1 :  Interleukin-1 
IFN-:  interferon-  
iNKT:  invariant natural killer cells  
KAT:  kynurenine aminotranferase 
KMO:   kynurenine-3-monoxygenase 
LPS:  bacterial lipoloysaccharides 
MCP-1:  monocyte chemoattractant protein-1 
NK:  natural killer cells  
NMDAR:  N-methyl-D-aspartate receptors  
RANTES: Regulated on Activation, Normal T-cell Expressed and Secreted  
ROS:  reactive oxygen species 
TDO:  tryptophan-2.3-dioxygenase 
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TGF- : transforming growth factor- 
Th1, Th2 T-helper cell populations  
TNF-: tumour necrosis factor- 
 
